Hemogenyx Pharmaceuticals PLC Placing to Raise GBP534,375 (9397U)
November 28 2023 - 6:19AM
UK Regulatory
TIDMHEMO
RNS Number : 9397U
Hemogenyx Pharmaceuticals PLC
28 November 2023
28 November 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO
ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS
UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS
ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF
ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH
FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 (" UK MAR"). IN ADDITION, MARKET SOUNDINGS
WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS
ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF
SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT,
THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION
OF INSIDE INFORMATION.
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Placing to Raise GBP534,375
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments for blood diseases,
is pleased to announce that it has successfully raised GBP534,375
(before expenses) through the allotment and issue of 22,500,000 new
ordinary shares at 2.375 pence per share (the "Placing", "Placing
Shares"). The Placing was oversubscribed and conducted on behalf of
the Company by its corporate broker, Peterhouse Capital
Limited.
The net proceeds from the Placing will be used to facilitate
progression of the Company's Chimeric Antigen Receptor ("CAR")
T-cells ("HEMO-CAR-T") for the treatment of acute myeloid leukaemia
("AML") . Specifically, and as outlined by the Company in its
announcement of 15 November 2023, this fundraise will help the
Company to accelerate the completion of work set out in the plan
presented and agreed to by the FDA and to re-submit the
Investigational New Drug ("IND") application for the HEMO-CAR-T
product. The funds will also enable the Company, in view of
recently announced successes, to provide modest additional
resources to the development of its CBR platform.
An application is being made to the London Stock Exchange Main
Market and admission of the Placing Shares to trading is expected
on or around 4 December 2023 ("Admission"). The Placing Shares will
rank pari passu with the existing ordinary shares in the
Company.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency
Rules, following Admission the enlarged issued share capital of the
Company will comprise 1,175,565,988 ordinary shares. The Company
does not hold any shares in treasury. The above figure may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company, under the
Disclosure Guidance and Transparency Rules.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented:
"The markets have at last started to recognise the significant
recent progress that the Company has made in the development of
both HEMO-CAR-T and CBR platform . Today's Placing will enable the
Company to progress with its ambitious schedule to move forward to
clinical trials of this exciting potential treatment for AML as
well as to further expand the use our CBR platform for the
treatment of solid tumours."
For the purposes of UK MAR, the person responsible for arranging
for the release of this Announcement on behalf of the Company is Dr
Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London , with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses
as engines for novel product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOELVLFLXFLFFBQ
(END) Dow Jones Newswires
November 28, 2023 07:19 ET (12:19 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024